Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rye

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Rye. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-000513-29 Sponsor Protocol Number: CLU-2008-001 Start Date*: 2008-09-30
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Efficacy and safety of subcutaneous cluster immunotherapy with cluster-allergoid CLUSTOID® (glutaraldehyde-polymerized allergen extract of mixtures of grass and rye allergens – Holcus lanatus, Dact...
    Medical condition: This clinical trial will evaluate the benefit of subcutaneous cluster immunotherapy with cluster-allergoid CLUSTOID® over placebo in patients with allergic rhinoconjunctivits.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005452-16 Sponsor Protocol Number: AL0705AV Start Date*: 2008-03-10
    Sponsor Name:Allergopharma Joachim Ganzer KG an afilliate of Merck KGaA, Darmstadt
    Full Title: A multicentre randomised placebo-controlled, double-blind clinical trial for eval¬ua¬tion of safety and efficacy of pre-seasonal specific immunotherapy with a hypoallergenic extract of a 6 grass an...
    Medical condition: IgE-mediated allergic diseases including symptoms of allergic rhinoconjunctivitis, controlled allergic bronchial asthma, triggered by grass/rye pollen allergens
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003006-26 Sponsor Protocol Number: VO52.06 Start Date*: 2006-11-03
    Sponsor Name:Stallergenes S.A.
    Full Title: A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III paediatric study of the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allerge...
    Medical condition: Grass Pollen Rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039085 Rhinitis allergic LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000455-12 Sponsor Protocol Number: SU-G-01 Start Date*: 2021-03-05
    Sponsor Name:ALK-Abelló A/S
    Full Title: A randomised, parallel-group, double-blind, placebo-controlled phase III trial assessing the efficacy and safety of 5-grass mix SLIT-drops in adults with grass pollen-induced rhinoconjunctivitis
    Medical condition: Grass pollen-induced allergic rhinoconjunctivitis for two years or more with or without asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) LV (Completed) CZ (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-001910-15 Sponsor Protocol Number: V034.04 Start Date*: 2004-11-22
    Sponsor Name:Stallergenes S.A.
    Full Title: Randomised, double-blind, placebo-controlled, multinational, multi-centre, Phase IIb / III study of the efficacy and safety of three doses of sublingual immunotherapy (SLIT) administered as tablets...
    Medical condition: Grass Pollen Related Allergic Rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10010744 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) HU (Completed) DE (Completed) AT (Completed) IT (Completed) ES (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002502-34 Sponsor Protocol Number: VO42.05 Start Date*: 2005-12-05
    Sponsor Name:Stallergenes S.A.
    Full Title: A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III paediatric study of the efficacy and safety of one dose of sublingual immunotherapy (SLIT) administered as al...
    Medical condition: Grass Pollen Related Allergic Rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10010744 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) DE (Completed) DK (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003258-98 Sponsor Protocol Number: VO53.06 Start Date*: 2007-04-11
    Sponsor Name:Stallergenes S.A.
    Full Title: A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III study to assess the long term efficacy, carry-over effect and safety of two dosing regimens of 300 IR subling...
    Medical condition: grass pollen rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039085 Rhinitis allergic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) SK (Completed) AT (Completed) DK (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000971-97 Sponsor Protocol Number: AL-X-01 Start Date*: 2017-08-23
    Sponsor Name:ALK Abelló A/S
    Full Title: Safety and tolerability of shortened up-dosing with Alutard SQ
    Medical condition: Allergic rhinoconjunctivitis induced by grass pollen, birch pollen and house dust mites
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000014962 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-006921-14 Sponsor Protocol Number: AF-H-01 Start Date*: 2009-02-09
    Sponsor Name:ALK-Abelló Arzneimittel GmbH
    Full Title: A multicentre randomised Phase II clinical trial to demonstrate equivalent pharmacodynamic efficacy and tolerability of two updosing schedules for ALK-Flex SQ
    Medical condition: Grass pollen induced allergic rhinoconjunctivitis requiring treatment during the grass pollen season
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000684-10 Sponsor Protocol Number: ME3301-12 Start Date*: 2004-10-28
    Sponsor Name:Meiji Seika Kaisha, Ltd.
    Full Title: A randomised, double-blind, placebo-controlled crossover study to investigate the efficacy and safety of three doses of ME3301 in patients with seasonal allergic rhinitis during allergen challenge ...
    Medical condition: seasonal allergic rhinitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003860-47 Sponsor Protocol Number: CIGE025ADE03 Start Date*: 2006-02-20
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, 20 week, double-blind, placebo-controlled, parallel-group, multiple-dose, multicenter study to assess the efficacy and safety of Omalizumab in combination with Depigoid, versus Depigo...
    Medical condition: Asthma extrinsic
    Disease: Version SOC Term Classification Code Term Level
    M15 10003558 LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000921-23 Sponsor Protocol Number: SHX0562 Start Date*: 2008-01-31
    Sponsor Name:ALK-SCHERAX Arzneimittel GmbH
    Full Title: A randomised, parallel-group, double-blind, placebo-controlled, multicentre Phase III trial assessing the pharmacodynamic efficacy and safety of an intraseasonal short-time updosing schedule for Al...
    Medical condition: Grass pollen induced allergic rhinoconjunctivitis requiring treatment during the grass pollen season.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001822-89 Sponsor Protocol Number: SMART_1_2012 Start Date*: 2012-08-21
    Sponsor Name:Lofarma S.p.A.
    Full Title: A Dose Finding Study of the Efficacy of LAIS® Birch-Alder tablets in patients suffering from tree pollen-induced allergic rhinoconjunctivitis
    Medical condition: Patients suffering from allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002501-23 Sponsor Protocol Number: V040.05 Start Date*: 2005-12-12
    Sponsor Name:Stallergenes S.A
    Full Title: A randomised, double-blind, placebo-controlled, multi-national, multi-centre, phase III extension study to assess the long term efficacy, safety and carry-over effect of one dose of sublingual imm...
    Medical condition: Grass Pollen Related Allergic Rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10010744 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended) CZ (Completed) SK (Completed) ES (Completed) DK (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003570-77 Sponsor Protocol Number: SB010/04/2012 Start Date*: 2012-12-04
    Sponsor Name:sterna biologicals GmbH & Co. KG
    Full Title: Clinical study to investigate safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple doses of the human GATA-3-specific DNAzyme solution SB010 in patients with mild aller...
    Medical condition: The trial will be conducted in 38 male patients with mild allergic asthma and documented or known biphasic reaction to allergen challenge (AC).
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003906-32 Sponsor Protocol Number: V060.08 Start Date*: 2008-11-26
    Sponsor Name:Stallergenes S.A.
    Full Title: A randomised, double-blind, placebo-controlled, multi national, Phase III study of the efficacy and safety of 300 IR sublingual immunotherapy (SLIT), starting 2 months before the grass pollen seaso...
    Medical condition: Grass pollen allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039085 Rhinitis allergic LLT
    9.1 10039085 Rhinitis allergic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002174-23 Sponsor Protocol Number: SMART_5 Start Date*: 2011-11-21
    Sponsor Name:Lofarma S.p.A.
    Full Title: A dose Finding Study of the Efficacy of LAIS Grass tablets in patients suffering from grass pollen-induced allergic rhinoconjunctivitis
    Medical condition: allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000617-20 Sponsor Protocol Number: SMART_2 Start Date*: 2013-08-23
    Sponsor Name:Lofarma S.p.A.
    Full Title: A Dose Finding Study of the Efficacy of LAIS® Mites Sublingual tablets in patients suffering from house dust mite-induced allergic rhinoconjunctivitis A prospective, double-blind, placebo-controlle...
    Medical condition: Patients suffering from allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005321-78 Sponsor Protocol Number: CQAW039X2201 Start Date*: 2013-04-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study evaluating efficacy and safety of QAW039 in the treatment of patients with moderate to severe atopic dermatitis
    Medical condition: Atopic dermatitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-005438-14 Sponsor Protocol Number: TAK-062-2001 Start Date*: 2022-11-15
    Sponsor Name:TAKEDA
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-062 for the Treatment of Active Celiac Disease in Subjects Attempting a Gluten...
    Medical condition: Active Celiac Disease in subjects attempting a Gluten-Free Diet
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10009839 Coeliac disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) Outside EU/EEA NL (Ongoing) BE (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 09:18:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA